Lymphangioleiomyomatosis: New Treatment Perspectives.
Identifieur interne : 000E79 ( Main/Exploration ); précédent : 000E78; suivant : 000E80Lymphangioleiomyomatosis: New Treatment Perspectives.
Auteurs : El Bieta Radzikowska [Pologne]Source :
- Lung [ 1432-1750 ] ; 2015.
Descripteurs français
- KwdFr :
- Animaux, Antagonistes des oestrogènes (usage thérapeutique), Autophagie (), Facteur de croissance endothéliale vasculaire de type D (antagonistes et inhibiteurs), Facteurs sexuels, Femelle, Humains, Immunothérapie, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Inhibiteurs de protéines kinases (usage thérapeutique), Kinase-2 cycline-dépendante (antagonistes et inhibiteurs), Lymphangioléiomyomatose (traitement médicamenteux), Metalloproteases (antagonistes et inhibiteurs), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs).
- MESH :
- antagonistes et inhibiteurs : Facteur de croissance endothéliale vasculaire de type D, Kinase-2 cycline-dépendante, Metalloproteases, Sérine-thréonine kinases TOR.
- traitement médicamenteux : Lymphangioléiomyomatose.
- usage thérapeutique : Antagonistes des oestrogènes, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Inhibiteurs de protéines kinases.
- Animaux, Autophagie, Facteurs sexuels, Femelle, Humains, Immunothérapie.
English descriptors
- KwdEn :
- Animals, Autophagy (drug effects), Cyclin-Dependent Kinase 2 (antagonists & inhibitors), Estrogen Antagonists (therapeutic use), Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Immunotherapy, Lymphangioleiomyomatosis (drug therapy), Metalloproteases (antagonists & inhibitors), Protein Kinase Inhibitors (therapeutic use), Sex Factors, TOR Serine-Threonine Kinases (antagonists & inhibitors), Vascular Endothelial Growth Factor D (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Cyclin-Dependent Kinase 2, Metalloproteases, TOR Serine-Threonine Kinases, Vascular Endothelial Growth Factor D.
- drug effects : Autophagy.
- drug therapy : Lymphangioleiomyomatosis.
- chemical , therapeutic use : Estrogen Antagonists, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Protein Kinase Inhibitors.
- Animals, Female, Humans, Immunotherapy, Sex Factors.
Abstract
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease, occurs in women, usually premenopausal, caused by the proliferation of neoplastic smooth muscle-derived cells. Mutations in the tuberous sclerosis complex genes, lead to the activation of mammalian target of rapamycin kinase (mTOR), results in proliferation of LAM cells, its increasing motility, and survival. Polycystic lung destruction, extensive involvement of lymphatic channels, chylothorax, chyloperitoneum, and renal angiomyolipomas can develop in LAM patients. The new, promising treatment strategies have been recently introduced due to discovery of the genetic and molecular mechanisms of LAM. Comprehension of the disease pathogenesis has resulted in the implementation of other therapeutic agents such as mTOR inhibitors, VEGF-D inhibitors, statins, interferon, chloroquine analogs, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, aromatase inhibitors, and their combinations. The mTOR inhibitors appear to be the most important, and the efficacy of sirolimus in LAM treatment has been proved. The article discussed the new control studies with mTOR inhibitors, doxycycline, simvastatin, and combination of them in LAM patients.
DOI: 10.1007/s00408-015-9742-6
PubMed: 25980593
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000249
- to stream PubMed, to step Curation: 000249
- to stream PubMed, to step Checkpoint: 000231
- to stream Ncbi, to step Merge: 000296
- to stream Ncbi, to step Curation: 000296
- to stream Ncbi, to step Checkpoint: 000296
- to stream Main, to step Merge: 000E80
- to stream Main, to step Curation: 000E79
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lymphangioleiomyomatosis: New Treatment Perspectives.</title><author><name sortKey="Radzikowska, El Bieta" sort="Radzikowska, El Bieta" uniqKey="Radzikowska E" first="El Bieta" last="Radzikowska">El Bieta Radzikowska</name><affiliation wicri:level="1"><nlm:affiliation>III Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Ul. Płocka 26, 01-138, Warsaw, Poland, e.radzikowska@wp.pl.</nlm:affiliation><country wicri:rule="url">Pologne</country><wicri:regionArea>III Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Ul. Płocka 26, 01-138, Warsaw, Poland</wicri:regionArea><wicri:noRegion>Poland</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25980593</idno><idno type="pmid">25980593</idno><idno type="doi">10.1007/s00408-015-9742-6</idno><idno type="wicri:Area/PubMed/Corpus">000249</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000249</idno><idno type="wicri:Area/PubMed/Curation">000249</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000249</idno><idno type="wicri:Area/PubMed/Checkpoint">000231</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000231</idno><idno type="wicri:Area/Ncbi/Merge">000296</idno><idno type="wicri:Area/Ncbi/Curation">000296</idno><idno type="wicri:Area/Ncbi/Checkpoint">000296</idno><idno type="wicri:Area/Main/Merge">000E80</idno><idno type="wicri:Area/Main/Curation">000E79</idno><idno type="wicri:Area/Main/Exploration">000E79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lymphangioleiomyomatosis: New Treatment Perspectives.</title><author><name sortKey="Radzikowska, El Bieta" sort="Radzikowska, El Bieta" uniqKey="Radzikowska E" first="El Bieta" last="Radzikowska">El Bieta Radzikowska</name><affiliation wicri:level="1"><nlm:affiliation>III Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Ul. Płocka 26, 01-138, Warsaw, Poland, e.radzikowska@wp.pl.</nlm:affiliation><country wicri:rule="url">Pologne</country><wicri:regionArea>III Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Ul. Płocka 26, 01-138, Warsaw, Poland</wicri:regionArea><wicri:noRegion>Poland</wicri:noRegion></affiliation></author></analytic><series><title level="j">Lung</title><idno type="eISSN">1432-1750</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Autophagy (drug effects)</term><term>Cyclin-Dependent Kinase 2 (antagonists & inhibitors)</term><term>Estrogen Antagonists (therapeutic use)</term><term>Female</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Immunotherapy</term><term>Lymphangioleiomyomatosis (drug therapy)</term><term>Metalloproteases (antagonists & inhibitors)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Sex Factors</term><term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term><term>Vascular Endothelial Growth Factor D (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antagonistes des oestrogènes (usage thérapeutique)</term><term>Autophagie ()</term><term>Facteur de croissance endothéliale vasculaire de type D (antagonistes et inhibiteurs)</term><term>Facteurs sexuels</term><term>Femelle</term><term>Humains</term><term>Immunothérapie</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Kinase-2 cycline-dépendante (antagonistes et inhibiteurs)</term><term>Lymphangioléiomyomatose (traitement médicamenteux)</term><term>Metalloproteases (antagonistes et inhibiteurs)</term><term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cyclin-Dependent Kinase 2</term><term>Metalloproteases</term><term>TOR Serine-Threonine Kinases</term><term>Vascular Endothelial Growth Factor D</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type D</term><term>Kinase-2 cycline-dépendante</term><term>Metalloproteases</term><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Autophagy</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphangioleiomyomatosis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Estrogen Antagonists</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term><term>Protein Kinase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphangioléiomyomatose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des oestrogènes</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Inhibiteurs de protéines kinases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Humans</term><term>Immunotherapy</term><term>Sex Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Autophagie</term><term>Facteurs sexuels</term><term>Femelle</term><term>Humains</term><term>Immunothérapie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphangioleiomyomatosis (LAM) is a rare multisystem disease, occurs in women, usually premenopausal, caused by the proliferation of neoplastic smooth muscle-derived cells. Mutations in the tuberous sclerosis complex genes, lead to the activation of mammalian target of rapamycin kinase (mTOR), results in proliferation of LAM cells, its increasing motility, and survival. Polycystic lung destruction, extensive involvement of lymphatic channels, chylothorax, chyloperitoneum, and renal angiomyolipomas can develop in LAM patients. The new, promising treatment strategies have been recently introduced due to discovery of the genetic and molecular mechanisms of LAM. Comprehension of the disease pathogenesis has resulted in the implementation of other therapeutic agents such as mTOR inhibitors, VEGF-D inhibitors, statins, interferon, chloroquine analogs, cyclin-dependent kinase inhibitors, matrix metalloproteinase inhibitors, aromatase inhibitors, and their combinations. The mTOR inhibitors appear to be the most important, and the efficacy of sirolimus in LAM treatment has been proved. The article discussed the new control studies with mTOR inhibitors, doxycycline, simvastatin, and combination of them in LAM patients. </div></front></TEI><affiliations><list><country><li>Pologne</li></country></list><tree><country name="Pologne"><noRegion><name sortKey="Radzikowska, El Bieta" sort="Radzikowska, El Bieta" uniqKey="Radzikowska E" first="El Bieta" last="Radzikowska">El Bieta Radzikowska</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25980593
|texte= Lymphangioleiomyomatosis: New Treatment Perspectives.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25980593" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |